Latest:
Dr. Meyerhardt on the Rationale for the CALGB/SWOG 80702 Trial in Colon Cancer
Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the rationale for the randomized phase 3 CALGB/SWOG 80702 trial in colon cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Catharine Young, PhD
Catharine Young, PhD, is a senior fellow at the Harvard T. H. Chan School of Public Health.
Latest:
How Enthusiasm for Science and Global Change Culminates in Wide-Reaching Opportunities to Improve Cancer Care: D. Ross Camidge, MD, PhD; and Catharine Young, PhD
Camidge and Young discuss Young's career, which combined her passions for science and global engagement and led her to a Cancer Moonshot leadership role.
Joel R. Hecht, MD
Latest:
Dr Hecht on Barriers to Enrollment into the BASECAMP-1 Study in Solid Tumors
J. Randolph (Randy) Hecht, MD, discusses barriers to enrollment in the observational BASECAMP-1 study and the phase 1/2 EVEREST-1 study, which will investigate HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in patients with solid tumors.
Shuntaro Ikegawa, MD, PhD
Latest:
Dr Ikegawa on An Analysis of Rapidly Manufactured Durcabtagene Autoleucel in R/R Multiple Myeloma
Shuntaro Ikegawa, MD, PhD, discusses results from a correlative analysis of an ongoing phase 1 trial evaluating the use of a novel T-Charge rapid manufacturing platform for the production of durcabtagene autoleucel CAR T-cells in multiple myeloma.
Josep Maria Piulats Rodriguez, MD, PhD
Latest:
Dr Piulats on Validating Predictive Biomarkers for Talazoparib Plus Enzalutamide in mCRPC
Josep Maria Piulats Rodriguez, MD, PhD, discusses next steps for validating predictive biomarkers of efficacy to treatment with talazoparib plus enzalutamide in mCRPC.
Andrew B. Smitherman, MD, MSc
Latest:
Biomarkers Help Predict the Role of Chemotherapy in Biologic Aging
Stimuli for biologic aging include ionizing radiation, ultraviolet light, diet, exercise, oxidative stresses, and perhaps, worst of all, smoking. All of these can trigger intracellular processes, including DNA methylation, or epigenetic change, telomere shortening and damage, DNA damage, and mitochondrial dysfunction.
Samuel Yamshon, MD
Samuel Yamshon, MD, is an assistant professor in the Department of Medicine at NYU Grossman School of Medicine, as well as the medical director of the Cellular Therapy Service at NYU Langone Health in New York, New York.
Latest:
Other Key Follicular Lymphoma Data From ASH 2024
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, discuss follicular lymphoma data from ASH 2024.
Sailaja Darisipudi
Latest:
Benefit of Elacestrant Improves With Longer Duration of CDK4/6 Inhibition in Patients With ER+/HER2– Metastatic Breast Cancer
Treatment with the oral selective estrogen receptor degrader elacestrant following treatment with CDK4/6 inhibitors improved progression-free survival outcomes vs standard care options in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.
Christina L. Roland, MD, PhD
Latest:
Dr. Roland on the Rationale to Examine Neoadjuvant Checkpoint Blockade in Sarcoma
Christina L. Roland, MD, MS, FACS, discusses the rationale of a phase 2 study evaluating neoadjuvant checkpoint blockade in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Jad Chahoud, MD, MPH, MHA
Jad Chahoud, MD, MPH, MHA, is an associate member in the Department of Genitourinary Oncology and medical director of IPOP at Moffitt Cancer Center.
Latest:
Dr Chahoud on the Safety of ALLO-316 in Advanced ccRCC
Jad Chahoud, MD, MPH, discusses the safety profile of ALLO-316 for the treatment of patients with advanced clear cell renal carcinoma.